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Abstract
Background. The implications of cannabis use in the onset of early psychosis and the severity of
psychotic symptoms have resulted in a proliferation of studies on this issue. However, few have
examined the effects of cannabis use on the cognitive symptoms of psychosis (i.e., neurocognitive
functioning) in patients with first-episode psychosis (FEP). This systematic review and meta-
analysis aim to assess the neurocognitive functioning of cannabis users (CU) and nonusers
(NU) with FEP.
Methods. Of the 110 studies identified through the systematic review of 6 databases, 7 met the
inclusion criteria, resulting in 14 independent samples and 78 effect sizes. The total sample
included 304 CU with FEP and 369 NU with FEP. The moderator variables were age at first use,
duration of use, percentage of males, and age.
Results. Effect sizes were not significantly different from zero in any neurocognitive domain
when users and NU were compared. Part of the variability in effect sizes was explained by the
inclusion of the followingmoderator variables: (1) frequency of cannabis use (β=0.013, F=7.56,
p=0.017); (2) first-generation antipsychotics (β=0.019, F=34.46, p≤ 0.001); and (3) country
where the study was carried out (β=0.266, t=2.06, p=0.043).
Conclusions. This meta-analysis indicates that cannabis use is not generally associated with
neurocognitive functioning in patients with FEP. However, it highlights the deleterious effect of
low doses of cannabis in some patients. It also stresses the importance of the type of antipsychotic
prescription and cannabis dose as moderator variables in the neurocognitive functioning of CU
with FEP.
Introduction
In most countries, cannabis is categorized as a drug of abuse, and its recreational use is strictly
prohibited [1], while in others it is perceived as a benign, relatively harmless substance [2,3]. This
antagonism could be explained in part by differences in the percentage of cannabis compounds
(mainly, tetrahydrocannabinol [THC] and cannabidiol [CBD]), which have geographical impli-
cations. Traditional production of cannabis resin (hashish), which remains prevalent in the Rif
(North Africa) [4], could generate a 60% more potent form of cannabis [5]. However, new
extraction techniques are now being used, mainly in central Europe and the United Kingdom, to
produce extremely high-potency concentrates containing up to 75% THC. These include skunk,
butane hash oil, and “Spice” [6,7].
Cannabis use may be considered a stressor for genetically vulnerable individuals [8–10].
Previous studies have reported that cannabis use increases the likelihood of early onset psychosis
in risky individuals [11–15], and it could worsen the severity of psychotic symptoms
[16–18]. Previous systematic reviews reported a twofold greater risk of developing a psychotic
disorder in cannabis users (CU) than in nonusers (NU) [19–21]. In addition, cannabis use may
induce acute cognitive effects that could diminish with abstinence [22]. Studies about the
biological basis of the effects of cannabis in the general population report that smoking cannabis
dysregulates the endocannabinoid system, which restores homeostasis in cases of severe brain
damage, such as inflammatory processes and neurocognitive impairment [23]. In patients with
first-episode psychosis (FEP), the various anomalies of the endogenous cannabinoid system
include potentially increased levels of cannabinoids in the frontal cortex and cerebrospinal fluid
even before the use of cannabis [24,25]. Hence, changes to this atypical endocannabinoid system
European Psychiatry
www.cambridge.org/epa
Review/Meta-analyses
Cite this article: Sánchez-Gutiérrez T,
Fernandez-Castilla B, Barbeito S, González-
Pinto A, Becerra-García JA, Calvo A (2020).
Cannabis use and nonuse in patients with
first-episode psychosis: A systematic review
and meta-analysis of studies comparing
neurocognitive functioning. European
Psychiatry, 63(1), e6, 1–10
https://doi.org/10.1192/j.eurpsy.2019.9
Received: 23 July 2019
Revised: 06 November 2019
Accepted: 19 November 2019
Key words:
Cannabis; first episode; marihuana;
neurocognition; psychosis
Author for correspondence:
Teresa Sánchez-Gutiérrez,
E-mail: teresa.sanchez@unir.net
© The Author(s) 2020. This is an Open Access
article, distributed under the terms of the
Creative Commons Attribution licence (http://
creativecommons.org/licenses/by/4.0/), which
permits unrestricted re-use, distribution, and
reproduction in any medium, provided the
original work is properly cited.
caused by external cannabinoid intake have been reported to be one
of the main risk factors for the onset of FEP [26]. A dose–response
relationship has been established for this risk-factor, namely, the
higher the levels of cannabis exposure, the higher the risk for onset
of psychosis [2,27,28]. Moreover, cannabis use may reduce the time
to onset of psychosis [29–31] and may affect neurocognitive func-
tioning [32]. The relationship between cannabis use and neurocog-
nitive functioning in FEP is supported by a considerable body of
empirical evidence. However, findings on the extent of this rela-
tionship are unclear. Several studies suggest a decrease in the
executive function, verbal memory and working memory of CU
with FEP [33,34], whereas other studies, including one meta-
analysis [35], show better performance in the neurocognitive func-
tion of this group [36–39] or even absence of neurocognitive
differences between CU and NU with FEP [40]. One of the expla-
nations for better neurocognitive performance is that patients who
were less impaired before onset of psychosis are more prone to use
cannabis [35]. The existence of moderators could explain some of
the heterogeneity of previous results. Older age has been associated
with better cognitive performance in verbal learning and verbal
fluency in patients who use cannabis [32], and patients with a
family history of psychosis performed better than patients without
a family history of psychosis in verbal memory and executive
function and had a higher global cognitive index [34].
This meta-analysis has the following objectives: (1) to provide a
systematic review of the literature on the effects of cannabis use on
neurocognitive functioning in patients with FEP; (2) to assess the
effects of cannabis use on the neurocognitive functioning of FEP
patients in eight domains, namely, premorbid and current intelli-
gence quotient, attention, executive function, working memory,
processing speed, verbal memory and learning, and visual memory;
(3) to examine whether age at first use, duration and frequency of
use, type of antipsychotic medication intake, sex, and age influenced
the relationship between cannabis use and neurocognitive function-
ing. We hypothesized that CU with FEP would have worse neuro-
cognitive functioning (with respect to worse attention, executive
function, and verbal memory) than NU with FEP. Our second
hypothesis was that a younger age at first use, a high frequency of
cannabis use, and therapywith first-generation antipsychoticswould
be related to decreased neurocognitive functioning in CU with FEP.
Methods
Search strategy
The search strategy was based on the Preferred Reporting Items for
Systematic Reviews and Meta-analyses (PRISMA-P) Statement
[41]. Articles were identified through extensive literature searches
using six online electronic databases: PubMed, ScienceDirect, Web
ofKnowledge,WileyCochrane Library, PsycInfo (EBSCOHost), and
SpringerLink. The search was limited to articles in English and only
peer-reviewed articles were considered. The systematic peer-review
of the literature was performed independently by two researchers
(T.S.-G. and S.B.). A third researcher (A.C.) was assigned for those
cases inwhich therewas no agreement in order to decidewhether the
manuscript met the criteria for inclusion. All of the researchers had
extended expertise in psychosis. The interrater agreement was 100%.
The keywords used were “first episode psychosis AND neurocogni-
tion AND cannabis,” “FEP AND cognition AND cannabis,” “Can-
nabis AND neurocog* AND neuropsycholog* AND FEP,”
“psychosis AND cognition AND cannabis,” “FEP AND IQ AND
cannabis,” “psychosis & IQ & cannabis,” and “FEP AND cognit*
AND cannabis.” Weekly bibliographical alerts were created in the
selected databases. These remained active until the date of submis-
sion of the present manuscript to ensure that the most recently
published studies were included. Reference lists from all the studies
included and from published reviews on cannabis, FEP, and neuro-
cognition were examined.
The initial search strategy yielded 4,691 studies that were
screened in the electronic databases. The abstract and methods
section were read. A total of 1,640 studies were excluded because
of repetition, and 2,941 were excluded because they did not fit the
inclusion criteria. This resulted in a final sample of 110 studies.
Further examination of the full texts of the 110 studies led to the
inclusion of 7 studies in the current review, with 14 independent
samples and 78 effect sizes. SupplementaryMaterial S1 shows a flow
chart of the search procedure and Table 1 shows the summarized
peer-reviewed data from the studies included in the meta-analysis.
Selection criteria and data extraction
Cross-sectional and longitudinal studies were included in the sys-
tematic reviewwhen theymet the following criteria: (1) diagnosis of
FEP according to the Diagnostic and Statistical Manual of Mental
Disorders (patients with psychotic symptoms who could have
received antipsychotic treatment for less than 12weeks); (2) com-
parison between CU with FEP and NU with FEP; (3) cannabis
abuse or dependence with no other comorbid substance use disor-
der (except for the commonmixture of tobacco and cannabis in the
same cigarette when patients did not report independent tobacco
use); (4) assessment of neuropsychological functioning based on
valid and reliable tests commonly used in clinical practice; and
(5) sufficient statistical data for transformation into effect sizes
from the original researchers. The reasons for exclusion were as
follows: (1) diagnosis of a category other than FEP within the
psychosis spectrum (e.g., schizophrenia, substance-induced psy-
chotic disorders, schizoaffective disorders); (2) studies on the
effects of individual components of cannabis on cognitive func-
tioning; (3) studies in which participants had poly-substance use
disorders, even if there was a preferential use toward cannabis,
given that other substances of abuse (e.g., alcohol, cocaine,
and stimulants) are associated with altered cognitive performance
[42,43]; (4) studies whose main neuropsychological outcomes
required MRI-based assessment; (5) available data on cannabis
use classified according to more than two different levels of use
(e.g., NU plus 2 or more cannabis use pathways).
The search was limited to studies published during the last
10 years (2008 to July 2018). The studies included were coded
according to the first author using a coding sheet. The outcome
variable was coded as “neurocognitive domains.” In some cases, the
neuropsychological instruments used to measure the cognitive
domains were different. Therefore, we grouped the subtest into
the following domains: current intelligence quotient (IQ), premor-
bid IQ, executive function, attention, working memory, verbal
memory and learning, visual memory, and processing speed.
Details on the correspondence between subtests and neuropsycho-
logical domains can be seen in Supplementary Material S2.
Other variables were coded according to whether they applied to
CUwith FEP or NUwith FEP. Themoderator variables collected in
the CU group were mean age at first use, mean duration of lifetime
cannabis use in years, and frequency of cannabis use, distinguishing
between low frequency (two times or less per week) and high
frequency (three times or more per week). Moreover, we extracted
the type of antipsychotic medication (coded as first-generation or
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Table 1. Selection of studies investigating cannabis use and neurocognitive functioning
Authors
Sample, mean age (male/
female) Design Neurocognitive measuresq Cannabis measures Cannabis diagnosis
Confounding
factors Main results
Cunha et al. [36] 28 FEPa CUf Age: 24.1
6.5 (18/50)
78 FEP NUg Age: 29.3
8.6 (18/50)
80 HCb Age: 30.4 8.3
(18/50)
Cross-
sectional
Attention: WAIS-IIId digits forward
subtest
Working memory: letter-number
sequencing
Verbal fluency and executive
functioning: FASh and COWATi
Age of first use, duration
(years), frequency (daily,
2–3 times/week, 1–3
times/month), current
cannabis use, previous
cannabis use
Use, abuse, and
dependence
Age and sex FEP CNU presented cognitive
impairments in attention compared
with HC and cognitive impairments in
working memory compared with FEP
CU and HC
Leeson et al. [37] 34 FEP NU Age: 28.29
10.87 (16/60)
65 FEP NU Age: 23.42
6.06 (16/60)
Longitudinal Verbal learning: Rey auditory verbal
learning task
Working memory manipulation:
CANTABj
Working memory span: CANTAB
Planning: Tower of London task (total
number of perfect solutions)
Premorbid IQc: WTARe
Current IQ: WAIS-III subtests:
information, block design,
arithmetic, and digit symbol
Frequency, years between
first cannabis use and
FEP onset, age of first
use
Use IQ Cannabis use may bring forward the
onset of psychosis in people who
otherwise have good prognostic
features, as indicated by premorbid
Cognition and social function
At the onset of psychosis, cannabis
users exhibited better cognitive
function than never-users and there
were no differential group, changes in
cognition over the following 15
months
The group differences in every subtest
vanished after the introduction of
premorbid IQ as a control variable,
thus reflecting higher intellectual
functioning in the cannabis users
prior to onset of psychosis
Rodríguez-
Sánchez et al.
[39]
47 FEP CU Age: 23.62
4.15 (15/60)
57 FEP NU Age: 30.04
8.47 (15/60)
37 HC Age: 25.24 7.87
(15/60)
Longitudinal Verbal memory: Rey auditory verbal
learning test
Visual memory: Rey complex figure
test
Motor speed: tapping test
Executive function: TMT-Bk
Working memory: WAIS-III backward
digits
Speed of processing: WAIS-III digit
symbol
Verbal fluency: FAS
Attention: number of correct
responses of CPTl
Motor coordination: Grooved
Pegboard (seconds to complete the
board with the dominant hand as
the dependent variable) Premorbid
IQ: WAIS-III vocabulary subtest
Frequency (within the
previous year), duration
(at program entry), and
age of first use
Use Age, years of
education,
premorbid IQ,
and baseline
performance in
follow-up
analysis
Cannabis users with schizophrenia have
better attention and executive
functions than nonusers at baseline
and after 1 year of treatment
Both groups of patients showed a
similar increase in their performance
in cognitive tasks during the 1-year
follow-up period
The amount of cannabis consumed and
the length of time of consumption did
not significantly influence cognitive
performance
Yücel et al. [38] 59 FEP CU Age: 20.7 2.8
26 FEPNU Age: 20.6 3.5
43 HC59 FEP CU Age:
21.6 5.8
Cross-
sectional
Premorbid IQ: National adult reading
test
Current IQ: WAIS-R
Processing speed: TMT-Am and digit
symbol coding
Verbal memory: Rey auditory verbal
learning test and the logical
memory component of the WMS-Rn
Visual memory: visual paired
associates (part I) and Visual
Age of first use, frequency,
recency
Use, abuse, and
dependence
Sex and age Comorbid cannabis use is associated
with a superior cognitive profile in
schizophrenia spectrum disorders
FEP patients who used cannabis
(especially those who used cannabis
prior to age 17) performed better than
nonusing patients and were less
impaired than healthy controls in
visual memory, working memory,
planning, and reasoning
Table 1. Continued
Authors
Sample, mean age (male/
female) Design Neurocognitive measuresq Cannabis measures Cannabis diagnosis
Confounding
factors Main results
Reproduction (part I) from the
WMS-R; spatial and pattern
recognition tests from the CANTAB
Working memory: spatial span and
spatial working memory from the
CANTAB
Executive functioning (planning and
reasoning): block design from the
WAIS-R and the Tower of London
de la Serna
et al. [42]
32 FEP CU Age: 16.34
0.16 (9/17)
76 FEP NU Age: 15.16
0.22 (9/17)
96 HC Age: 15.18 0.19
(9/17)
Cross-
sectional
Attention: WAIS-III digits forward,
TMT-A, Stroop test (words + colors),
CPT (number of correct responses
and average time reaction)
Working memory: WAIS-III digits
backward, WAIS-III number-letter
sequencing
Learning and memory: TAVECo
Executive functions: TMT-B, FAS and
COWAT, Stroop test (interference),
WCSTp
Presence or absence of
cannabis use in the
previous month
Use Age,
socioeconomic
status
Significant differences in overall
cognitive functioning in controls
compared with both groups of
patients (CU and NU)
Better cognitive functioning in the CU
group compared with the NU group
on tasks assessing attention and
executive functions
Mata et al. [33] 61 FEP CU Age: 23.42
4.14 (9/17)
71 FEP NU Age: 29.54
8.44 (9/17)
Cross-
sectional
Premorbid IQ: verbal comprehension
index (WAIS-III)
Decision-making: Iowa gambling task
Working memory: WAIS-III digits
backward
Executive function: FAS and TMT-A and
TMT-B
Presence or absence of
cannabis use in the
previous year
Use, abuse, and
dependence
Age and sex,
previous use of
other drugs
Cannabis abuse prior to the onset of
psychosis is associated with greater
impairment in a decision-making task
linked to orbitofrontal function but
not with more severe deficits in the
performance of working memory and
executive function tasks, which are
sensitive to dorsolateral prefrontal
function
Patients who abused cannabis also had
lower estimated IQ than nonusers
Moreno
Granados
et al. (2014)
41 FEP Age: 16.15 2.6
(12–18)
39 HC Age: 17.38 2.37
(12–18)
Cross-
sectional
Verbal memory: WMS-III
Visual memory: Rey complex figure
test
Frequency of lifetime use,
age at first use, current
use, lifetime exposure,
severity
Use, abuse, and
dependence
Age and sex,
previous use of
other drugs
A significant interaction of time by group
was observed in the processing speed
domain, only in the male subgroup.
However, among patients with
schizophrenia, cannabis users
performed better than nonusers
aFEP: first-episode psychosis.
bHC: healthy controls.
cIQ: intelligence quotient.
dWAIS-III: Wechsler Adult Intelligence Scale, 3rd edition.
eWTAR: Wechsler test of adult reading.
fCU: cannabis users.
gNU: nonusers.
hFAS: verbal fluency test.
iCOWAT: Controlled Oral Word Association.
jCANTAB: Cambridge Automated Neuropsychological Test Automated Battery.
kTMT-B: trail making test, part B.
lCPT: continuous performance test.
mTMT-A: trail making test, part A.
nWMS-R: Wechsler Memory Scale-Revised.
oTAVEC: Test de Aprendizaje Verbal España-Complutense (Spanish version of the California verbal learning test.
pWCST: Wisconsin Card Sorting Test Index.
qAuthors of each study did not provide a global or independent score for each of the domains that were measured. See Table 2 for the correspondence between the subtest and the neuropsychological domains.
second-generation antipsychotics) and sociodemographic data
such as sex, age, and country where the study was performed.
Interrater agreement for the calculated effect was 100%.
Calculations and analyses
From each study, the information needed to calculate standardized
mean differences (Cohen’s d) and their sampling variances was
extracted. This information consisted of the means, SDs, and
sample sizes of the two independent groups (CU and NU).
Standardized mean differences were then corrected for bias by
transforming them to Hedges’ g [44]. A positive Hedges’ g indicates
that NU score higher in cognitive tests than CU.
All studies reported more than one effect size, because the
independent groups were compared in several domains of neuro-
cognitive performance (see Supplementary Material S2). Since
effect sizes extracted from the same sample are related to each
other, the application of classic meta-analytic techniques would
violate the assumption of independent effect sizes. Violating this
assumption, that is, ignoring dependency among effect sizes, can
lead to a biased estimate of the standard error of the pooled effect
and biased variance component estimates [45]. Therefore, in order
to account for dependent effect sizes, a three-level model was
applied [46,47]. With the application of a three-level model, it is
possible to model three different sources of variance: the sampling
variance observed at Level 1 (which is known and calculated
beforehand), the variance between the effect sizes belonging to
the same study at Level 2 (within-study variance), and the variance
between study effects at Level 3 (between-studies variance).
Log-likelihood-ratio-tests were performed to determine
whether the within-study (Level 2) and between-studies (Level 3)
variances were significant [48]. These tests compare the deviance of
the full model (three-level model) with the deviance of the model
where the between-studies variance has been ignored and with the
deviance of a model that does not take into account the within-
study variance. If the results of these two tests are statistically
significant, then it can be concluded that there is significant vari-
ance at both levels. Furthermore, the percentage of variability due to
systematic differences between studies, due to systematic differ-
ences within studies, and due to sampling variance was calculated
using the formulae of Cheung [49]. In order to explain these
variances, moderator variables were introduced in the model one
by one. Continuous moderator variables (i.e., age at first use,
duration of use, percentage of low-frequency users, percentage of
high-frequency users, percentage of participants taking first-
generation antipsychotics, percentage of participants taking
second-generation antipsychotics, percentage of men, and age)
were centered to their mean for ease of interpretation. For some
moderator variables (i.e., age, percentage of men, percentage of
participants taking first-generation antipsychotics, and percentage
of participants taking second-generation antipsychotics), the infor-
mation was available for both the user group and the nonuser
group. Therefore, we first performed an independent t test, and if
no differences were found between CU and NU, the values of the
moderator variables were averaged across the groups. However, if
differences between the groups emerged, we performed a two-step
analysis in which the data from moderators of the CU group were
first introduced in the model, followed by the moderator referring
to the NU group.
The validity of the results of themeta-analysis was threatened by
possible publication bias. That is, if studies reporting nonsignificant
results were censored or had never been submitted for publication,
our sample of studies could be biased, as could, therefore, our
results [50]. In this meta-analysis, the presence of publication bias
was evaluated by visually inspecting the funnel plot [51] and by
applying a three-level version of the Egger regression test [52].
We also performed sensitivity analyses for outliers by excluding,
one by one, effect sizes that were larger or smaller than two SDs
above/below the mean.
All analyses were performed with the PROCMIXED procedure
in SAS, which uses restrictedmaximum likelihood as the estimation
method. Funnel plots were generated with R.
Results
Final sample of studies
The meta-analysis of the effect of cannabis use on neurocognitive
performance in patients with FEP contained 7 independent studies
(k) reporting on 78 effect sizes (m) and a total sample of 673 sub-
jects. The sample consisted of 304 subjects in the CU group and
369 subjects in the NU group.
Overall analyses
The three-level meta-analysis resulted in a nonsignificant overall
effect of 0.05 (SE = 0.15, p=0.96, 95% confidence interval [CI;
0.39, 0.37]). The log-likelihood-ratio tests revealed that the
between-studies variance was not statistically significant (χ2=
2.30, df=1, p= 0.13), while the within-study variance was statisti-
cally significant (χ2=640.2, df=1, p< 0.001). Around 8.5% of the
total variance in effect sizes was due to differences between studies,
86.7% of the total variance between effect sizes was attributed to
differences within studies, and 4.8% of the observed variability was
due to sampling variance.
Independent analysis of neurocognitive domains
Nonsignificant effects were observed in the analyses of each of the
cognitive domains separately: (1) attention (d=0.35, p=0.68);
(2) executive function (d=0.16, p=0.59); (3) premorbid IQ (d=
0.10, p=0.72); (4) processing speed (d=0.15, p=0.69); (5) verbal
memory and learning (d=0.005, p=0.98); (6) visual memory (d
=0.08, p=0.78); and (7) working memory (d=0.04, p=0.90; see
Table 2). Figure 1 shows the caterpillar plot where all the effect sizes
are represented.
Moderator analyses
The independent t tests revealed no differences between CU and
NU regarding the percentage of participants taking first-
and second-generation antipsychotic medication (t= 0.314, df=
6, p= 0.37 for both analyses). Similarly, no differences were found
in the mean age (t= 0.233, df= 10, p= 0.23), although there
were differences across groups regarding the percentage of men
(t= 5.307, df= 10, p< 0.001). This percentage was higher in CU
(mean= 75.35, SD= 5.77) than in NU (mean = 52.39, SD= 8.88).
Therefore, we present the effect of the percentage of men in CU
and the percentage of men in NU separately.
When analyzing the effects of the moderator variables on can-
nabis use and neurocognitive functioning, we found that a low
frequency of use led to a more positive effect size, that is, the
difference in the neurocognitive functioning between CU and NU
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was greater, in favor of NU (F= 7.56, df=1, 12.5, p= 0.02).
Moreover, the use of first-generation antipsychotics led to a
greater difference in neurocognitive functioning between the
groups (F= 34.46, df=1, 47, p< 0.001). Finally, the country where
the study took place influenced the neurocognitive functioning of
both groups (F= 3.75, df= 3, 70.5, p=0.01, see Table 3).
Sensitivity analyses
Five outliers were detected (three positive and two negative), all in
the study of de la Serna et al. [53]. By deleting each of these outliers
one by one and performing the analyses again each time, the overall
effect ranged from 0.004 (95% CI [0.44, 0.433], p=0.98) to
0.04 (95% CI [0.37, 0.29], p=0.84). These results indicate that
the overall estimate is quite robust.
Publication bias
Figure 2 shows the funnel plot with all of the effect sizes. The fact
that effect sizes are symmetrically distributed around the mean
effect seems to indicate the absence of publication bias.
Furthermore, the three-level Egger regression test showed no
significant association between the standard errors and their cor-
responding effect sizes (F= 0.01, df=1, 14.64, p= 0.97).
Discussion
The results of this three-level model meta-analysis revealed no
significant differences between CU and NU with respect to neuro-
cognitive functioning. These findings are consistent with those of
some previous studies, which show an absence of differences in
neurocognitive functioning betweenCU andNUwith FEP [40], but
not with those of others [32]. The lack of significant differences in
neurocognitive functioning between CU and NU with FEP in this
study could be explained by the fact that vulnerable patients with
better cognitive function can develop psychosis owing to cannabis
use; this subsample can mask the deleterious effect of cannabis on
cognition in other patient groups. In addition, the results can be
explained by the different times of exposure to cannabis. Cumula-
tive exposure to cannabis in a developing vulnerable adolescent
brain accounts for an increased risk of onset of psychosis and,
Table 2. Analyses of the effects of cannabis use on the neuropsychological performance domains
Outcome variablesa kc md ne CUf n CNUg βh (SE)i 95% CIj t (df )k pl
Overall 7 78 304 369 0.009 (0.155) (0.389, 0.372) 0.06 (6.54) 0.957
Attention 3 8 107 211 0.350 (0.806) (2.262, 1.561) 0.43 (6.90) 0.677
Executive function 6 28 292 342 0.165 (0.283) (0.618, 0.949) 0.58 (4.06) 0.591
Premorbid IQb 4 4 232 188 0.097 (0.248) (0.692, 0.886) 0.39 (3) 0.721
Processing speed 2 3 106 83 0.150 (0.280) (3.408, 3.708) 0.53 (1) 0.687
Verbal memory and learning 5 14 215 220 0.005 (0.183) (0.400, 0.389) 0.03 (13) 0.977
Visual memory 3 7 118 110 0.076 (0.244) (1.138, 0.984) 0.31 (1.98) 0.783
Working memory 6 10 292 342 0.037 (0.295) (0.800, 0.725) 0.13 (4.92) 0.904
aFor motor coordination and current IQ, there were not enough observations to perform the analyses.
bFor premorbid IQ, a standard two-level random effects model was applied because there was only one outcome per study.
ck: number of studies that report information about the moderator variable.
dm: number of effect sizes that report information about the moderator variable.
en: sample size.
fCU: cannabis user group.
gCNU: cannabis nonuser group.
hβ: mean effect size.
iSE: standard error.
jCI: confidence interval.
kdf: degrees of freedom.
lp: significant p value (p≤ 0.005).
Figure 1. Caterpillar plot. Individual effect sizes (n = 78) of all of the cognitive domains (attention, executive function, processing speed, verbal memory and learning, visual
memory, working memory, and premorbid IQ) are represented.
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therefore, the manifestation of its symptoms [16-18], including the
effects of the disease itself on neurocognitive functioning [32]. The
present results may have been masked by the different durations of
cannabis use. However, most of these results have to be interpreted
with caution owing to the small number of observations
(i.e., processing speed and current IQ), thus revealing the lack of
sufficient power to detect a significant effect. Future research might
investigate the effect of duration of cannabis exposure prior to the
onset of FEP and test whether longer exposures translate into effects
on neurocognitive functioning.
The analysis of the moderator variables showed that the percent-
age of participants who less frequently used cannabis had a more
positive influence on the pooled effect, that is, the higher the number
of participants who used cannabis less frequently, the better the
performance of the NU in cognitive domains (and the worse the
performance of users). This remarkable and counterintuitive result
can be explained by differences in the underlying mechanism of
psychosis associated with frequency of use for CU. Heavy, repeated
cannabis use, particularly during adolescence in patients without
psychosis, has been associated with adverse effects on the endocan-
nabinoid system, especially in genetically predisposed persons
[54]. Chronic and heavy use of cannabis in persons without psycho-
sis affects cognitive domains such as memory and attention, as well
as their associated brain areas [55]. However, heavy use in patients
with a very high genetic risk (family history of psychosis) is associ-
ated with better results in some cognitive domains, such as verbal
learning [29]. As for lower use of cannabis and psychosis, a recent
study found a cluster association between poor cognition and low
cannabis use in comparison with moderate and heavy use [56]. The
endocannabinoid system restores homeostasis in brain functioning
Table 3. Moderator effect of selected variables on cannabis use and neurocognitive functioning
Moderator variable ka nb βc Fd dfe pf
Duration 4 36 0.038 0.05 1, 1.88 0.851
Age of first use 4 36 0.649 3.41 1, 2.05 0.203
Low frequency CU 3 15 0.013 7.56 1, 12.5 0.017
High frequency CU 3 15 0.041 2.37 1, 1 0.366
Medication FGg 4 49 0.019 34.46 1, 47 <0.001
CU% menh 6 72 0.006 0.03 1, 3.16 0.881
CNU% meni 6 72 0.026 1.27 1, 4.42 0.317
% men 7 78 0.038 1.17 1, 8.73 0.309
Age 7 78 0.029 0.72 1, 4.9 0.437
Country 3.75 3, 70.5 0.015
United Kingdom 1 6 0.353 t =0.92 68.0 0.358
Brazil 1 3 0.760 t =1.40 68.9 0.166
Spain 4 53 0.266 t = 2.06 68.9 0.043
Australia 1 16 0.403 t =1.71 69.6 0.091
ak: number of studies that report information about the moderator variable.
bn: number of effect sizes that report information about the moderator variable.
cβ: mean effect size.
dF: Value of the statistic Snedecor’s F
edf: degrees of freedom.
fp: significant p value (p≤0.005).
gFG: first generation antipsychotics.
hCU: cannabis users.
iCNU: cannabis nonunsers. Probability values in bold represent significant results (p ≤ 0.05).
Figure 2. Funnel plot. The fact that effect sizes are symmetrically distributed around the mean effect seems to indicate the absence of publication bias.
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during brain damage, such as the neurocognitive impairment that is
observed in patients with psychosis [23]. The presence of exogenous
cannabis is one of the main factors accounting for the dysregulation
of the endocannabinoid system [26]. As a result, the use of cannabis,
even at low doses, in adolescents with a low threshold for developing
psychosis after cannabis use may trigger the dysregulation of this
system and accelerate the incidence of positive, negative, affective,
and cognitive psychotic symptoms [16-18,32]. Consequently, the
results of the present meta-analysis may support the finding that
cannabis use acts as a risk factor for the worsening of cognitive
function in a subsample of patients with a low threshold for devel-
oping FEP in CU [33,36,37]. Further analysis must investigate
whether cognition in this subsample improves once cannabis is no
longer used.
The analysis revealed significant effects of first-generation
antipsychotics and second-generation antipsychotics. Within the
group of patients taking first-generation antipsychotics, the
percentage of drugs increased with differences in neurocognitive
functioning betweenCUandNUwith FEP. Thus, CU scored higher
in all of the neurocognitive domains despite the absence of signif-
icant results. These findings are consistent with studies on the
differential antidopaminergic effects of first and second-generation
antipsychotics and the disturbing effects of cannabis use on the
homeostatic effects of endocannabinoids such as anandamide and
2-arachidonoylglycerol (2-AG) [57,58]. FEP patients present
increased endocannabinoid levels in the frontal cortex and in
cerebrospinal fluid even before using cannabis [24,25]. This was
mainly due to the counteracting effects of anandamide and 2-AG in
patients with psychosis and in individuals at risk for psychosis
who present increased levels of dopamine in the mesolimbic areas
[59-61]. The endocannabinoid system increases the level of
anandamide and 2-AG to naturally balance dopamine hyperactiva-
tion in mesolimbic areas [62]. However, first-generation antipsy-
chotics antagonize the postsynaptic dopaminergic D2 receptors,
thus decreasing levels of dopamine [63] and helping endocannabi-
noids to achieve homeostasis. This pharmacological action implies
an excessive decrease in dopamine in the mesocortical circuits, thus
increasing the onset of negative and cognitive symptoms. In
contrast, second-generation antipsychotics interact not only with
the dopamine system, but also with the serotoninergic neurotrans-
mitter system [64], thus decreasing the incidence of negative
and cognitive symptoms of psychosis [57]. Cannabis use may
dysregulate both the homeostasis task of the endocannabinoid
system [65,66] and worsen the pharmacological effects of antipsy-
chotics. This result may have clinical implications for the develop-
ment of patient-focused medicine, which implies the selection of
second-generation antipsychotics in CU.
Our study also reveals a significant country effect. It seems that
studies performed in Spain yielded a higher (positive) effect size,
which was significantly different from zero, meaning that NU score
higher than CU in cognitive domains. In contrast, no significant
effects were found in the other countries. These results should be
interpreted with caution because most of the studies that met the
criteria for the present meta-analysis were carried out in Spain.
Consequently, Spain is overrepresented in our data. Even so, this
outcome might be explained by the differences in cannabis prepara-
tions worldwide and the use of genetically modified plants with a
high THC content, such as the popular skunk or sinsemilla, which is
used predominantly in Central Europe and the UK [4,5,7]. These
cannabis products have significantly decreased CBD [67], one of the
several cannabinoids present in the Cannabis sativa plants. CBD has
shown antipsychotic properties and preserves cognitive deterioration
effects in patients with psychosis [68-70]. In conclusion, the dose,
frequency, and different types of cannabis preparationsmay interfere
with the neurocognitive functioning of CU with FEP.
The results of this study show the importance of some moder-
ators in the cognitive skills of patients with psychosis. However, as
these results are associations, we cannot infer causal relationships.
In addition, heavy cannabis use in patients with chronic schizo-
phrenia leads to worse cognitive performance than in moderate
users [56], and this can be explained by the deleterious chronic
effect of cannabis use in the long term, a finding not reported in the
FEP samples studied in our meta-analysis. In addition, it is impor-
tant to remember that quitting cannabis improves functionality in
FEP in the long term [29,34].
The strengths of the present study include the focus on a large
sample of FEP patients and specific neurocognitive domains and the
inclusion of studies in which patients only used cannabis. The study
takes into account the shortcomings of previous systematic reviews
and meta-analyses. Furthermore, the multilevel approach made it
possible to include moderator variables. Therefore, we were able to
assess the influence of cannabis duration and frequency of use, as
well as demographic and clinical variables, on neurocognitive
functioning outcomes [46,47], thus gaining more insight into inter-
ference with the neurocognitive performance of FEP patients. Our
study is also subject to a series of limitations. First, the relatively small
number of effect sizes in some of the neurocognitive domains
analyzed couldmean that the statistical power is insufficient to detect
a significant effect between the groups. Second, some moderator
variables, such as the country where the study was developed, were
very uneven in terms of observations within categories. Other mod-
erator variables such as, the educational level, whichwas described as
a potential variable that could influence cognitive functioning [71]
and antipsychotic dosage were not included in this study. Only the
study of Yücel et al. [38] comprised doses of chlorpromazine equiv-
alents for each comparison group. Future studies in this field could
consider the selection of these moderator variables to analyze its
relationship with cognitive functioning in cannabis-users. Third, the
consideration of antipsychotic treatment for the definition of FEP
was not a homogenous criterion in each of the studies. While the
studies of Cunha et al. [36], Yücel et al. [38], de la Serna et al. [53],
and Moreno-Granados et al. [72] did not include information
regarding previous antipsychotic treatment to the enrollment in
the study, the studies of Leeson et al. [37], Rodríguez-Sánchez
et al. [39], and Mata et al. [33] enrolled FEP patients who could
have received neurolepticmedication formore than 12, 6, or 4weeks,
respectively. Future researchmay account for this limitation in order
to observe if there were any cofounding effects regarding antipsy-
choticmedication exposition at the onset of the disorder. Fourth, due
to the wide exclusion criteria selected for this study, it could be
considered that the sample obtained for this meta-analysis is not
naturalistic. Finally, all of the studies included in the meta-analysis
were cross-sectional; therefore, a longitudinal follow-up of these
studies could help elucidate whether the absence of differences, the
duration of psychosis, and the level of cumulative cannabis exposure
all remain the same.
Conclusions
In conclusion, the current study shows that cannabis use is not
related to the neurocognitive functioning of patients with FEP. It
also highlights the importance of moderators. Future research is
needed to understand how the neurocognitive functioning of
patients with FEP is affected by dose, duration of cannabis
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exposure, and different types of cannabis preparations, as well as
the potential interactions between antipsychotic medication and
cannabis use.
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